SMO is a component of the Hedgehog signaling pathway (Figure 1). SMO and PTCH1 are transmembrane receptor proteins that deliver signals from Hedgehog ligands to cells. Mutations in PTCH1 or SMO that lead to constitutive activation of SMO are known to play a role in carcinogenesis of basal cell carcinoma, glioblastoma, medulloblastoma, and rhabdomyosarcoma (Onishi and Katano 2011).

The Hedgehog signaling pathway is a critical part of embryonic development (Athar et al. 2006). In skin, Hedgehog proteins are involved in maintenance of stem cells, development of hair follicles, development of glands, and regulation of skin growth (Athar et al. 2006).

After embryonic development, the Hedgehog pathway is not active in most human tissues (Rudin 2012). Reactivation of this pathway can lead or contribute to carcinogenesis (Onishi and Katano 2011).

SMO was identified as a therapeutic target by Hahn et al. (1996) and Johnson et al. (1996) (Rudin 2012). SMO inhibitors, exemplified by cyclopamine, bind strongly to the SMO receptor, which results in suppression of Hedgehog signaling (Robarge et al. 2009; Rudin 2012).


Figure 1. Schematic of the Hedgehog signaling pathway.

Related Pathways

Contributors: Charles Rudin, M.D., Ph.D.

Suggested Citation: Rudin, C. 2015. SMO. My Cancer Genome (Updated December 2015)

Modified: December 4, 2015

Disclaimer: The information presented at is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.